Literature DB >> 17115297

The management of hydronephrosis in patients undergoing TURBT.

N Thiruchelvam1, G Ubhayakar, H Mostafid.   

Abstract

OBJECTIVE: Previous studies have shown the negative prognostic correlation of hydronephrosis in bladder cancer; however, practical uncertainties remain regarding the management of these patients.
METHODS: We retrospectively reviewed the notes of patients undergoing TURBT over a three year period and recorded the management and outcome of patients with hydronephrosis.
RESULTS: Six percent with bladder cancer had hydronephrosis. Nearly all the cases had muscle invasive disease. At TURBT, the ureteric orifice was seen in 41%; in the remaining 59% of patients, the ureteric orifice was involved and resected. This resolved the hydronephrosis in only one patient (who had superficial disease).
CONCLUSIONS: Hydronephrosis in bladder cancer is associated with a poor prognosis. The hydronephrosis does not resolve with resection alone. As awaiting it's resolution may delay definitive treatment, we suggest aggressive management of hydronephrosis from the time of initial diagnosis with ureteric stenting in order to protect renal units and optimize renal function prior to further definitive treatment of bladder cancer.

Entities:  

Mesh:

Year:  2006        PMID: 17115297     DOI: 10.1007/s11255-005-4794-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  18 in total

1.  Relationship of MRI and clinical staging to outcome in invasive bladder cancer treated by radiotherapy.

Authors:  P Robinson; C D Collins; W D Ryder; B M Carrington; C E Hutchinson; D Bell; J P Logue; G Read; R A Cowan
Journal:  Clin Radiol       Date:  2000-04       Impact factor: 2.350

2.  The treatment of bladder carcinoma by local excision and fulguration.

Authors:  J A NICHOLS; V F MARSHALL
Journal:  Cancer       Date:  1956 May-Jun       Impact factor: 6.860

3.  Carcinoma of the bladder: a computer analysis of 516 patients.

Authors:  W T Bowles; I Silber
Journal:  J Urol       Date:  1972-02       Impact factor: 7.450

4.  The roentgenographic diagnosis of obstructive lesions of the ureter.

Authors:  E K Lang; M Nourse
Journal:  J Urol       Date:  1969-06       Impact factor: 7.450

5.  The value of excretory urography in staging bladder cancer.

Authors:  T R Hatch; J M Barry
Journal:  J Urol       Date:  1986-01       Impact factor: 7.450

6.  The origin of regenerative bladder mucosa after partial mucosal stripping.

Authors:  J G Connolly; A Morales; L Minnaker; H Raeburn
Journal:  Invest Urol       Date:  1971-03

7.  The prognostic significance of ureteral obstruction in carcinoma of the bladder.

Authors:  R Greiner; C Skaleric; P Veraguth
Journal:  Int J Radiat Oncol Biol Phys       Date:  1977 Nov-Dec       Impact factor: 7.038

8.  A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer.

Authors:  S A Hussain; D D Moffitt; J G Glaholm; D Peake; D M Wallace; N D James
Journal:  Ann Oncol       Date:  2001-07       Impact factor: 32.976

9.  Intravenous urography as a prognostic indicator in vesical carcinoma.

Authors:  R P Golding; T E van Zanten; A H Tierie; J J Batterman; G Hart
Journal:  Cancer       Date:  1987-08-15       Impact factor: 6.860

10.  Hydronephrosis as a prognostic indicator in bladder cancer patients.

Authors:  G E Haleblian; E C Skinner; M G Dickinson; G Lieskovsky; S D Boyd; D G Skinner
Journal:  J Urol       Date:  1998-12       Impact factor: 7.450

View more
  2 in total

Review 1.  Defining cisplatin eligibility in patients with muscle-invasive bladder cancer.

Authors:  Di Maria Jiang; Shilpa Gupta; Abhijat Kitchlu; Alejandro Meraz-Munoz; Scott A North; Nimira S Alimohamed; Normand Blais; Srikala S Sridhar
Journal:  Nat Rev Urol       Date:  2021-01-11       Impact factor: 14.432

Review 2.  Kidney ultrasound - what is important for a urologist?

Authors:  Tomasz Szopiński; Elżbieta Keller; František Záťura
Journal:  J Ultrason       Date:  2016-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.